STRYKER CORP 03/08/2023
Consolidated net sales of $5.0 billion increased 11.2% in the quarter and 11.9% in constant currency. Organic net sales increased 11.9% in the quarter including 11.4% from increased unit volume…
Consolidated net sales of $5.0 billion increased 11.2% in the quarter and 11.9% in constant currency. Organic net sales increased 11.9% in the quarter including 11.4% from increased unit volume…
Flow Traders, reported its financial results for the six months ending on June 30, 2023. The gross trading income for this period amounted to $301.5 million, demonstrating consistent performance compared…
Regeneron delivered strong financial results in the second quarter of 2023 through increasingly diversified revenue streams, and we remain well-positioned for long-term growth. Net product sales of EYLEA in the…
Strong operational performance drove cash flow from operations of $3.1 billion and cash flow from operations before working capital of $2.7 billion. Capital spending of $1.6 billion, resulting in quarterly…
Jones Lang LaSalle Incorporated reported operating income of $149.2 million for the second quarter of 2023. Diluted earnings per share were $0.05 and adjusted diluted earnings per share1 were $0.50…
For the quarter ended June 30, 2023, consolidated net income attributable to ICE was $799 million on $1.9 billion of consolidated revenues, less transaction-based expenses. Second quarter GAAP diluted earnings…
Net income was $68 million in the second quarter of 2023 compared to $206 million in the second quarter of 2022. Adjusted net income was $88 million in the second…
The Hasbro team delivered a solid second quarter, with revenue ahead of our expectations, significant reduction of inventory, and meaningful progress toward our transformation and cost savings programs. Q2 Hasbro,…
Applications and Commerce revenue grew 11% exceeding guide. Delivered $83 million net income and $265 million normalized EBITDA. Repurchased $746 million in shares through July 2023 reducing share count by…
11% year-over-year growth across our base business was driven by our diverse portfolio of therapies for HIV, Oncology, and Liver Disease. We received positive regulatory updates for six of our…